Solid Biosciences Inc.
Simbolis: SLDB
NASDAQ
9.54
USDRinkos kaina šiandien
-2.0678
P/E santykis
0.0530
PEG koeficientas
360.20M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Solid Biosciences Inc. (SLDB) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 612.23 | 123.6 | 213.7 | 207.8 | |||||||||
balance-sheet.row.short-term-investments | 232.96 | 49.6 | 58.3 | 88.6 | |||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 6 | |||||||||
balance-sheet.row.other-current-assets | 14.25 | 6.1 | 5.9 | 8.7 | |||||||||
balance-sheet.row.total-current-assets | 636.16 | 129.7 | 219.6 | 222.6 | |||||||||
balance-sheet.row.property-plant-equipment-net | 139.54 | 33.2 | 38.6 | 7.6 | |||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-investments | 7.33 | 1.8 | 1.8 | 2.1 | |||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.other-non-current-assets | 0.94 | 0.2 | 0.2 | 0.1 | |||||||||
balance-sheet.row.total-non-current-assets | 147.82 | 35.2 | 40.6 | 9.8 | |||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-assets | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.account-payables | 12.49 | 2 | 3.2 | 4.5 | |||||||||
balance-sheet.row.short-term-debt | 9.14 | 2.3 | 2.6 | 1.5 | |||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.long-term-debt-total | 99.13 | 23.9 | 26 | 0.6 | |||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||
balance-sheet.row.other-current-liab | 22.88 | 10.2 | 16.7 | 9.6 | |||||||||
balance-sheet.row.total-non-current-liabilities | 99.13 | 23.9 | 26.1 | 0.6 | |||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.capital-lease-obligations | 105.95 | 23.9 | 28.5 | 2.1 | |||||||||
balance-sheet.row.total-liab | 165.62 | 38.5 | 48.6 | 24.2 | |||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.common-stock | 0.08 | 0 | 0 | 0.1 | |||||||||
balance-sheet.row.retained-earnings | -2507.41 | -658.8 | -562.7 | -476.8 | |||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0.04 | 0 | -0.1 | 0 | |||||||||
balance-sheet.row.other-total-stockholders-equity | 3125.66 | 785.2 | 774.5 | 684.9 | |||||||||
balance-sheet.row.total-stockholders-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 783.98 | 164.9 | 260.3 | 232.4 | |||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||
balance-sheet.row.total-equity | 618.36 | 126.5 | 211.7 | 208.2 | |||||||||
balance-sheet.row.total-liabilities-and-total-equity | 783.98 | - | - | - | |||||||||
Total Investments | 234.79 | 51.5 | 58.3 | 88.6 | |||||||||
balance-sheet.row.total-debt | 108.27 | 26.3 | 28.5 | 2.1 | |||||||||
balance-sheet.row.net-debt | -271 | -47.8 | -126.8 | -117.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -96.02 | -96 | -86 | -72.2 | |||||||||
cash-flows.row.depreciation-and-amortization | 2.96 | 2.6 | 2.4 | 3 | |||||||||
cash-flows.row.deferred-income-tax | -46.06 | -13.6 | 0 | 1.2 | |||||||||
cash-flows.row.stock-based-compensation | 7.63 | 7.6 | 7.5 | 13.4 | |||||||||
cash-flows.row.change-in-working-capital | -6.34 | -6.3 | -3.7 | -23 | |||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.1 | -0.1 | |||||||||
cash-flows.row.inventory | 0 | 0 | 0 | -11.5 | |||||||||
cash-flows.row.account-payables | -0.76 | -0.8 | -5.2 | 1.2 | |||||||||
cash-flows.row.other-working-capital | -4.67 | -5.6 | 1.4 | -12.6 | |||||||||
cash-flows.row.other-non-cash-items | 43.65 | 11.5 | -18.3 | -0.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -94.18 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.acquisitions-net | 26.56 | -9.7 | 31.5 | 89.8 | |||||||||
cash-flows.row.purchases-of-investments | -117.43 | -117.4 | -182.8 | -141.2 | |||||||||
cash-flows.row.sales-maturities-of-investments | 128.63 | 128.6 | 212.8 | 51.4 | |||||||||
cash-flows.row.other-investing-activites | 11.2 | 9.7 | 0.6 | -89.8 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 9.69 | 9.7 | 59.2 | -91.1 | |||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||||
cash-flows.row.common-stock-issued | 5.51 | 3 | 72.6 | 134.9 | |||||||||
cash-flows.row.common-stock-repurchased | 0.16 | 0 | 0 | 0 | |||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-financing-activites | -5.16 | 0.1 | 2.3 | 0.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.74 | 3.1 | 74.8 | 135 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 76.19 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | -81.37 | -81.4 | 36 | -33.9 | |||||||||
cash-flows.row.cash-at-end-of-period | 384.77 | 74 | 157.2 | 121.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 466.14 | 155.4 | 121.2 | 155.1 | |||||||||
cash-flows.row.operating-cash-flow | -94.18 | -94.2 | -98 | -77.8 | |||||||||
cash-flows.row.capital-expenditure | -1.51 | -1.5 | -3 | -1.3 | |||||||||
cash-flows.row.free-cash-flow | -95.69 | -95.7 | -101 | -79 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 8.1 | 13.6 | |||||||||
income-statement-row.row.cost-of-revenue | 2.96 | 2.6 | 2.4 | 58.7 | |||||||||
income-statement-row.row.gross-profit | -2.96 | -2.6 | 5.7 | -45.1 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 76.56 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 27.75 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.operating-expenses | 103.73 | 101.7 | 107.4 | 85.9 | |||||||||
income-statement-row.row.cost-and-expenses | 104.31 | 104.3 | 107.4 | 85.9 | |||||||||
income-statement-row.row.interest-income | 7.14 | 7.1 | 2.6 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.59 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 1.09 | 0 | -0.4 | 0 | |||||||||
income-statement-row.row.total-operating-expenses | 6.35 | 8.3 | 20.5 | 0.1 | |||||||||
income-statement-row.row.interest-expense | -1.96 | 0 | -20.5 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 2.96 | 2.6 | -1.5 | 3 | |||||||||
income-statement-row.row.ebitda-caps | -102.01 | - | - | - | |||||||||
income-statement-row.row.operating-income | -104.25 | -104.3 | -106.5 | -72.3 | |||||||||
income-statement-row.row.income-before-tax | -96.02 | -96 | -86 | -72.2 | |||||||||
income-statement-row.row.income-tax-expense | -4.56 | 0 | -20.5 | -0.1 | |||||||||
income-statement-row.row.net-income | -94.06 | -96 | -65.5 | -72.1 |
Dažnai užduodami klausimai
Kas yra Solid Biosciences Inc. (SLDB) bendras turtas?
Solid Biosciences Inc. (SLDB) bendras turtas yra 164939000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -4.694.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra Solid Biosciences Inc. (SLDB) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -96015000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 26265000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 101734000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 74015000.000.